Recombinant virus production using mammalian cells in suspension

ABSTRACT

The invention generally provides methods for producing recombinant AAV viral particles using cells grown in suspension. The invention provides recombinant AAV particles for use in methods for delivering genes encoding therapeutic proteins, and methods for using the recombinant AAV particles in gene therapy.

RELATED APPLICATIONS

This application is a continuation of International Application No.:PCT/US2009/000577, filed Jan. 29, 20009, which claims the benefit ofU.S. Provisional Application No. 61/062,819, filed Jan. 29, 2008, theentire contents of each of which are expressly incorporated herein byreference.

BACKGROUND OF THE INVENTION

The present invention relates to the field of viral based gene therapy,in particular to recombinant adeno-associated virus (rAAV) based genetherapy. The invention relates to methods for producing recombinant AAVviral particles using cells grown in suspension. The invention providesrecombinant AAV particles for use in methods for delivering genesencoding therapeutic proteins, and methods for using the recombinant AAVparticles in in vivo or in ex vivo gene therapy.

The present invention seeks to overcome some of the deficiencies in theprior art by addressing problems that limit production of rAAV vectorsin sufficient quantities for efficient gene therapy procedures. It isapparent from the foregoing that there is a clear need for improvedlarge-scale methods for production of high titer infectious rAAV andimproved production methods can include different techniques to makeproduction more efficient.

Using methods and materials disclosed herein, infectious rAAV can beobtained in mammalian cell lines grown in suspension including thosethat have not been genetically altered by recombinant geneticengineering for improved rAAV production.

SUMMARY OF THE INVENTION

The present invention seeks to overcome some of the deficiencies in theprior art by addressing problems that limit production of rAAV insufficient quantities for clinical and commercial application. Becausethe quantity of virus that is required for clinical application, anefficient and scalable method of virus production is required. Thisinvention provides an efficient and scalable method for producingrecombinant AAV viral particles by utilizing cells grown in suspension.

The invention is based, in part, on a novel method for producing hightiter rAAV as described in U.S. application Ser. No. 11/503,775,entitled Recombinant AAV Production in Mammalian Cells, filed Aug. 14,2007, which is a continuation-in-part of U.S. application Ser. No.10/252,182, entitled High Titer Recombinant AAV Production, filed Sep.23, 2002, now U.S. Pat. No. 7,091,029, issued Aug. 15, 2006. Thecontents of all the aforementioned applications are hereby incorporatedby reference in their entirety.

In the method described herein, mammalian cells are simultaneously orsequentially co-infected within several hours with at least tworecombinant herpes simplex viruses (rHSV). The two rHSV are vectorsdesigned to provide the cells, upon infection, with all of thecomponents necessary to produce rAAV. The method does not require theuse of mammalian cells specialized for expression of particular geneproducts. This is advantageous because the invention can be practicedusing any mammalian cell generally suitable for this purpose.

Examples of suitable genetically unmodified mammalian cells include butare not limited to cell lines such as HEK-293 (293), Vero, RD, BHK-21,HT-1080, A549, Cos-7, ARPE-19, and MRC-5.

In a first aspect, the invention features a method for producingrecombinant AAV viral particles in a mammalian cell comprisingco-infecting a mammalian cell capable of growing in suspension with afirst recombinant herpesvirus (rHSV) comprising a nucleic acid encodingan AAV rep and an AAV cap gene each operably linked to a promoter; and(ii) a second rHSV comprising a gene of interest, and a promoteroperably linked to said gene of interest; and allowing the virus toinfect the mammalian cell; thereby producing recombinant AAV viralparticles in a mammalian cell.

In one embodiment, the gene of interest is a therapeutic gene.

In another embodiment, the therapeutic gene is selected from the groupconsisting of: an angiogenesis inhibiting gene (AI), alpha-1antitrypsin, retinoschisin, acid alpha glucosidase, and RPE65. Incertain embodiments, the angiogenesis inhibiting gene is sFlt01.

In a further embodiment, the AAV cap gene has a serotype selected fromthe group consisting of AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7,and AAV-8, AAV-9, and rh-AAV-10.

In another aspect, the invention features a method for producingrecombinant AAV viral particles in a mammalian cell comprisingco-infecting a mammalian cell capable of growing in suspension with afirst recombinant herpesvirus comprising a nucleic acid encoding an AAVrep2 and an AAV cap 1 or cap 2 gene each operably linked to a promoter;and (ii) a second recombinant herpesvirus comprising a therapeutic genelike an alpha 1 antitrypsin gene, and a promoter operably linked to saidgene; and allowing the virus to infect the mammalian cell, therebyproducing recombinant AAV viral particles in a mammalian cell.

In one embodiment of the aspects described above, the mammalian cell isselected from the group consisting of: BHK, HEK-293 (293), Vero, RD,HT-1080, A549, Cos-7, ARPE-19, and MRC-5.

In another aspect, the invention features a method for producingrecombinant AAV viral particles in a BHK cell comprising co-infecting aBHK cell capable of growing in suspension with a first recombinantherpesvirus comprising a nucleic acid encoding an AAV rep and an AAV capgene each operably linked to a promoter; and (ii) a second recombinantherpesvirus comprising a gene of interest, and a promoter operablylinked to said gene of interest; and allowing the virus to infect theBHK cell; thereby producing recombinant AAV viral particles in a BHKcell.

In yet another aspect the invention features a method for producingrecombinant viral particles in a BHK cell comprising co-infecting a BHKcell capable of growing in suspension with a first recombinantherpesvirus comprising a nucleic acid encoding an AAV rep2 and an AAVcap1, -2, -5, or -8 gene each operably linked to a promoter; and (ii) asecond recombinant herpesvirus comprising an AI gene or an alpha 1antitrypsin gene, and a promoter operably linked to said gene ofinterest; and allowing the virus to infect the BHK cell; therebyproducing recombinant viral particles in a BHK cell.

In an embodiment of the method of any one of the above-mentioned claims,the herpesvirus is a virus selected from the group herpesviridaeconsisting of cytomegalovirus (CMV), herpes simplex (HSV), varicellazoster (VZV), and epstein barr virus (EBV), Kaposi sarcoma-associatedvirus (KSHV), human herpesvirus 6a and 6b (HHV6a and HHV6b), and humanherpesvirus 7 (HHV7).

In another embodiment, the herpesvirus is replication defective.

In another embodiment, the gene of interest is a therapeutic gene.

In a further embodiment, the therapeutic gene is selected from the groupconsisting of an anti-angiogenic genes, alpha-1 antitrypsin,retinoschisin, acid alpha glucosidase, RPE65, beta-subunit of the conephotoreceptor cGMP-gated channel (CNGB-3), alpha-subunit of the conephotoreceptor cGMP-gated channel (CNGA-3), cone photoreceptor G-proteinalpha-subunit (GNAT2), Retinal pigment epithelium-specific 65 kDa(RPE65), X-linked juvenile retinoschisis (RS1), Brain-derivedneurotrophic factor (BDNF), Glial cell-derived neurotrophic factor(GDNF), Myotonic dystrophy protein kinase (DMPK), CCHC-type zinc finger,nucleic acid binding protein (known as CNBP or ZNF9), Retinitispigmentosa GTPase regulator (RPGR), Acid α-glucosidase (GAA),Choroideremia (CHM), Rab escort protein-1 (REP1), Alpha-synuclein(SNCA), Coagulation factor VIII, procoagulant component (hemophilia A orF8), Coagulation factor IX (plasma thromboplastic component, Christmasdisease, hemophilia B or F9), Aryl hydrocarbon receptor interactingprotein-like 1 (AIPL1), X-linked Inhibitor of Apoptosis Protein (XIAP),clarin-1 (CLRN1), Leber's hereditary neuropathy genes (MT-ND1, MT-ND4,MT-ND4L, and MT-ND6), alpha-galactosidase A (α-Gal A) orAlpha-L-iduronidase.

In still another embodiment, the AAV cap gene has a serotype selectedfrom the group consisting of AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6,AAV-7, AAV-8, AAV-9, and rhAAV-10.

In another embodiment of any one of the above-mentioned aspects, themethod further comprises the step of determining multiplicity ofinfection (MOI). In a related embodiment, the total MOI is between 3 and14.

In one embodiment of any one of the above-mentioned aspects, theco-infection is simultaneous.

In another aspect, the invention features a method for producingrecombinant viral particles in a BHK cell comprising simultaneouslyco-infecting a BHK cell capable of growing in suspension with a firstrecombinant Herpes Family virus comprising a nucleic acid encoding anAAV rep and an AAV cap gene each operably linked to a promoter; and (ii)a second recombinant Herpes Family virus comprising a gene of interest,and a promoter operably linked to said gene of interest, allowing thevirus to infect the BHK cell; and purifying the viral particles, therebyproducing recombinant viral particles in a BHK cell.

In a further aspect, the invention features a method for producingrecombinant viral particles in a BHK cell comprising simultaneouslyco-infecting a BHK cell capable of growing in suspension with a firstrecombinant herpesvirus comprising a nucleic acid encoding an AAV repand an AAV cap gene each operably linked to a promoter; and (ii) asecond recombinant herpesvirus comprising an AI gene or an alpha 1antitrypsin gene, and a promoter operably linked to said gene ofinterest, allowing the virus to infect the BHK cell; and purifying theviral particles; thereby producing recombinant viral particles in a BHKcell.

In one embodiment of the above aspects, the herpesvirus is a virusselected from the group consisting of HSV-1, HSV-2, HHV-3, HHV-4, HHV-5,HHV-6, HHV-7, HHV-8. In a further embodiment, the herpesvirus is a humanherpesvirus selected from the group consisting of: human herpesvirusestypes 1, 2, 3, 4, 5, 6A, 6B, 7, and 8.

In another embodiment, the recombinant herpesvirus is replicationdefective.

In a further embodiment, the gene of interest is a therapeutic gene.

In another further embodiment, the therapeutic gene is selected from thegroup consisting of: anti-angiogenic genes, alpha-1 antitrypsin,retinoschisin, acid alpha glucosidase, RPE65, beta-subunit of the conephotoreceptor cGMP-gated channel (CNGB-3), alpha-subunit of the conephotoreceptor cGMP-gated channel (CNGA-3), cone photoreceptor G-proteinalpha-subunit (GNAT2), Retinal pigment epithelium-specific 65 kDa(RPE65), X-linked juvenile retinoschisis (RS1), Brain-derivedneurotrophic factor (BDNF), Glial cell-derived neurotrophic factor(GDNF), Myotonic dystrophy protein kinase (DMPK), CCHC-type zinc finger,nucleic acid binding protein (known as CNBP or ZNF9), Retinitispigmentosa GTPase regulator (RPGR), Acid α-glucosidase (GAA),Choroideremia (CHM), Rab escort protein-1 (REP1), Alpha-synuclein(SNCA), Coagulation factor VIII, procoagulant component (hemophilia A orF8), Coagulation factor IX (plasma thromboplastic component, Christmasdisease, hemophilia B or F9), Aryl hydrocarbon receptor interactingprotein-like 1 (AIPL1), X-linked Inhibitor of Apoptosis Protein (XIAP),clarin-1 (CLRN1), Leber's hereditary neuropathy genes (MT-ND1, MT-ND4,MT-ND4L, and MT-ND6), alpha-galactosidase A (α-Gal A) orAlpha-L-iduronidase.

In still another embodiment, the AAV cap gene has a serotype selectedfrom the group consisting of AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6,AAV-7, AAV-8, AAV-9, and rhAAV-10.

In another embodiment, the invention features a method for producingrecombinant viral particles in a mammalian cell according to any one ofthe aspects as described above, whereby the number of viral particlesproduced is equal to or greater than the number of viral particles grownin an equal number of cells under adherent conditions.

In another aspect, the invention features a recombinant AAV viralparticle produced in a mammalian cell by the method comprisingco-infecting a mammalian cell capable of growing in suspension with afirst recombinant herpesvirus comprising a nucleic acid encoding an AAVrep and an AAV cap gene each operably linked to a promoter; and (ii) asecond recombinant herpesvirus comprising a gene of interest, and apromoter operably linked to said gene of interest; and allowing thevirus to infect the mammalian cell; thereby producing recombinant AAVviral particles in a mammalian cell.

In one embodiment, the herpesvirus is a virus selected from the groupconsisting of: cytomegalovirus (CMV), herpes simplex (HSV) and varicellazoster (VZV) and epstein barr virus (EBV).

In another embodiment, the recombinant herpesvirus is replicationdefective.

In still another embodiment, the gene of interest is a therapeutic gene.

In yet another further embodiment, the therapeutic gene is selected fromthe group consisting of: anti-angiogenic genes, alpha-1 antitrypsin,retinoschisin, acid alpha glucosidase, RPE65, beta-subunit of the conephotoreceptor cGMP-gated channel (CNGB-3), alpha-subunit of the conephotoreceptor cGMP-gated channel (CNGA-3), cone photoreceptor G-proteinalpha-subunit (GNAT2), Retinal pigment epithelium-specific 65 kDa(RPE65), X-linked juvenile retinoschisis (RS1), Brain-derivedneurotrophic factor (BDNF), Glial cell-derived neurotrophic factor(GDNF), Myotonic dystrophy protein kinase (DMPK), CCHC-type zinc finger,nucleic acid binding protein (known as CNBP or ZNF9), Retinitispigmentosa GTPase regulator (RPGR), Acid α-glucosidase (GAA),Choroideremia (CHM), Rab escort protein-1 (REP1), Alpha-synuclein(SNCA), Coagulation factor VIII, procoagulant component (hemophilia A orF8), Coagulation factor IX (plasma thromboplastic component, Christmasdisease, hemophilia B or F9), Aryl hydrocarbon receptor interactingprotein-like 1 (AIPL1), X-linked Inhibitor of Apoptosis Protein (XIAP),clarin-1 (CLRN1), Leber's hereditary neuropathy genes (MT-ND1, MT-ND4,MT-ND4L, and MT-ND6), alpha-galactosidase A (α-Gal A) orAlpha-L-iduronidase.

In another embodiment, the gene of interest is a reporter gene.

In a further embodiment, the AAV cap gene has a serotype selected fromthe group consisting of AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7,AAV-8, AAV-9, and rhAAV-10.

In another aspect, the invention features a recombinant AAV viralparticle produced in a BHK cell comprising co-infecting a BHK cellcapable of growing in suspension with a first recombinant herpesviruscomprising a nucleic acid encoding an AAV rep and an AAV cap gene eachoperably linked to a promoter; and (ii) a second herpesvirus comprisinga gene of interest, and a promoter operably linked to said gene ofinterest; and allowing the virus to infect the BHK cell; therebyproducing recombinant AAV viral particles in a BHK cell.

In another aspect, the invention features a method for delivering anucleic acid sequence encoding a therapeutic protein to a target cell,the method comprising co-infecting a mammalian cell capable of growingin suspension with a first recombinant herpesvirus comprising a nucleicacid encoding an AAV rep and an AAV cap gene each operably linked to apromoter; and (ii) a second herpesvirus comprising a gene of interest,wherein the gene of interest comprises a therapeutic gene, and apromoter operably linked to said gene of interest; and allowing thevirus to infect the mammalian cell and express the nucleic acid sequenceencoding a therapeutic protein; thereby delivering a nucleic acidsequence encoding a therapeutic protein to the target cell.

In one embodiment, the herpesvirus is a virus selected from the groupconsisting of: cytomegalovirus (CMV), herpes simplex (HSV) and varicellazoster (VZV) and epstein barr virus (EBV).

In another embodiment, the recombinant Herpes Family virus isreplication defective.

In a further embodiment, the gene of interest is a therapeutic gene.

In still another embodiment, the therapeutic gene is selected from thegroup consisting of: anti-angiogenic genes, alpha-1 antitrypsin,retinoschisin, acid alpha glucosidase, RPE65, beta-subunit of the conephotoreceptor cGMP-gated channel (CNGB-3), alpha-subunit of the conephotoreceptor cGMP-gated channel (CNGA-3), cone photoreceptor G-proteinalpha-subunit (GNAT2), Retinal pigment epithelium-specific 65 kDa(RPE65), X-linked juvenile retinoschisis (RS1), Brain-derivedneurotrophic factor (BDNF), Glial cell-derived neurotrophic factor(GDNF), Myotonic dystrophy protein kinase (DMPK), CCHC-type zinc finger,nucleic acid binding protein (known as CNBP or ZNF9), Retinitispigmentosa GTPase regulator (RPGR), Acid α-glucosidase (GAA),Choroideremia (CHM), Rab escort protein-1 (REP1), Alpha-synuclein(SNCA), Coagulation factor VIII, procoagulant component (hemophilia A orF8), Coagulation factor IX (plasma thromboplastic component, Christmasdisease, hemophilia B or F9), Aryl hydrocarbon receptor interactingprotein-like 1 (AIPL1), X-linked Inhibitor of Apoptosis Protein (XIAP),clarin-1 (CLRN1), Leber's hereditary neuropathy genes (MT-ND1, MT-ND4,MT-ND4L, and MT-ND6), alpha-galactosidase A (α-Gal A) orAlpha-L-iduronidase.

In a further embodiment, the AAV cap gene has a serotype selected fromthe group consisting of AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7,AAV-8, AAV-9, and rhAAV-10.

In another aspect, the invention features a kit for making a recombinantviral particle in a mammalian cell that is capable of growing insuspension, and instructions for use.

In yet another aspect, the invention features a kit for delivering anucleic acid sequence encoding a therapeutic protein to a target cellaccording to claim 33, and instructions for use.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a graph that shows a comparison of rAAV production by twodifferent isolates of suspension BHK cells. Suspension BHK isolatesC13-2P (4.5×10⁵ cells/mL) and AC9 (4.7×10⁵ cells/mL) were co-infectedwith rHSV-rep2cap2 and rHSV-GFP at a multiplicity of infection (MOI) of12 and 2, respectively. Samples of the production over time were assayedfor the level of rAAV2-GFP production by the green-cell infectivityassay.

FIG. 2 is a graph that shows rAAV production over time. Cells wereco-infected at 1.0×10⁶ cells/mL with rHSV-rep2cap2 and rHSV-GFP at anMOI of 12 and 2, respectively. Two hours post-infection, cells werepelleted and resuspended in DMEM without FBS. Samples of the productionover time were assayed for the level of rAAV2-GFP production by thegreen-cell infectivity assay. Error bars represent the standarddeviation over 3 flasks.

FIG. 3 is a graph that shows cell density at infection. sBHK cells atthe range of cell densities indicated in a total volume of 25 mL wereco-infected with rHSV-rep2cap2 and rHSV-GFP at an MOI of 12 and 2,respectively. Two hours post-infection, cells were pelleted andresuspended in DMEM without FBS. Samples were harvested by in situ lysisat 22 hpi and were assayed for the level of rAAV2-GFP production(ip/cell—bars; total ip in the 25 mL culture—open circles) by thegreen-cell infectivity assay. Error bars represent the intra-assayvariation.

FIG. 4 (A and B) is two graphs that show rAAV production over of rangeof MOI for rHSV-rep2cap2. FIG. 4A shows cumulative data for experimentsexamining rAAV production with rHSV-rep2cap2 used in co-infections overthe indicated range of MOIs. All co-infections were performed withrHSV-GFP used at an MOI of 2 and cells were infected at densitiesranging from 8.13×10⁵ to 3.76×10⁶ cells/mL. Two hours post-infection,cells were pelleted and resuspended in DMEM without FBS. Samples wereharvested by in situ lysis between 18 and 48 hpi and were assayed forthe level of rAAV2-GFP production by the green-cell infectivity assay.The numbers inside the bars represent the number of flasks assayed atthe indicated MOI. Error bars represent inter-assay variation. FIG. 4Bshows DNAse-resistant particle (DRP) and ip production by sBHK cellswith rHSV-rep2cap2 used at varying MOIs. Representative samples (n=2)from graph A were also assayed for the level of DRP produced (line). Themean ip/cell of those samples is presented as well (bars). The mean DRPto ip ratio is 13.8 (+/−3.2) to 1.

FIG. 5 is a graph that shows rAAV production over of range of MOI forrHSV-rep2cap1. Cumulative data for experiments examining rAAV productionwith rHSV-rep2cap1 used in co-infections over the indicated range ofMOIs is presented. All co-infections were performed with rHSV-AAT usedat an MOI of 2 and cells were infected at densities ranging from1.45×10⁶ to 2.40×10⁶ cells/mL. Two hours post-infection, cells werepelleted and resuspended in DMEM without FBS. Samples were harvested byin situ lysis between 23 and 48 hpi and were assayed for the level ofrAAV1-AAT production by the DNAse-resistant particle—quantitativereal-time PCR. The numbers inside the bars represent the number offlasks assayed at the indicated MOI. Error bars represent inter-assayvariation.

FIG. 6A is a graph that shows production levels of rAAV of differentcapsid serotypes (1, 2, 5, 8, and 9) with different transgenes (AI, AAT,and GFP). All co-infections were performed with rHSV-rep2capX at an MOIof 4 and rHSV-GOI at an MOI of 2 and cells were infected at densitiesranging from 1.2×10⁶ to 2.0×10⁶ cells/mL. Two hours post-infection,cells were pelleted and resuspended in DMEM without FBS. Samples wereharvested by in situ lysis between 24 and 30 hpi and were assayed forthe level of rAAVX-GOI production by the DNAse-resistantparticle—quantitative real-time PCR. Error bars represent inter-assayvariation. Representative samples from the experiments in FIG. 6A wereassayed for infectivity using the TCID₅₀ end-point dilution assay. TheDRP/infectivity ratios (DRP:ip) are depicted in FIG. 6B. The differencesin infectivity between the three serotypes indicated (rAAV types 1, 2,and 5), reflect the differences in these cell types in their ability toinfect the HeLa-derived cells used in the infectivity assay.

FIG. 7 is a graph that shows rAAV2-GFP production in a Celligen PlusCSTR. At 24 hpi, the DRP:ip was 10:1 and the capsid:DRP was 4.4:1(cell-associated vector). During cell growth, the average doubling timewas 9.6 h.

FIG. 8 is a graph that shows the results of an experiment that is arepeat of rAAV2-GFP production in a Celligen Plus CSTR as shown in FIG.7. The DRP:ip was 11:1 and the capsid:DRP was 6.6:1 (cell-associatedvector).

FIG. 9 is a graph that shows pre-infection sBHK growth in Wavebioreactors as a function of time for fed-batch and perfusion runs.

FIG. 10 is a graph that shows typical rAAV1-AAT specific yields(DRP/cell) for Wave disposable bioreactor vector production at 1/2 L (49hpi. n=3. rHSV-rep2cap1 MOI of 12 and rHSV-AAT MOI of 2), 5/10 L (24hpi, n=4. rHSV-rep2cap1 MOI of 4 and rHSV-AAT MOI of 2), and 10/20 L (24hpi, n=6, rHSV-rep2cap1 MOI of 4 and rHSV-AAT MOI of 2) culture scales.

FIG. 11 is a graph that shows metabolite concentrations during a 1 Lfed-batch sBHK rAAV1-AAT production run, pre- and post-infection.

FIG. 12 is a graph that shows typical metabolite concentrations during a1 L perfusion sBHK rAAV1-AAT production run, pre- and post-infection.

FIG. 13 is a graph that shows typical cell growth and viability for a 5L culture volume Wave bioreactor batch run.

FIG. 14 is a graph that shows typical cell growth, viability, andammonium concentrations for a 10 L culture volume Wave bioreactor batchrun.

DETAILED DESCRIPTION OF THE INVENTION

The invention generally provides methods for producing recombinant AAVviral particles, using cells grown in suspension, and their use inmethods of gene therapy.

Definitions

Unless defined otherwise, all technical and scientific terms used hereinhave the meaning commonly understood by a person skilled in the art towhich this invention belongs. The following references provide one ofskill with a general definition of many of the terms used in thisinvention: Singleton et al., Dictionary of Microbiology and MolecularBiology (2nd ed. 1994); The Cambridge Dictionary of Science andTechnology (Walker ed., 1988); The Glossary of Genetics, 5th Ed., R.Rieger et al. (eds.), Springer Verlag (1991); and Hale & Marham, TheHarper Collins Dictionary of Biology (1991). As used herein, thefollowing terms have the meanings ascribed to them below, unlessspecified otherwise.

As used herein, the term “gene” or “coding sequence” refers to a DNAregion (the transcribed region) which encodes a protein. A codingsequence is transcribed (DNA) and translated (RNA) into a polypeptidewhen placed under the control of an appropriate regulatory region, suchas a promoter. A gene may comprise several operably linked fragments,such as a promoter, a 5′ leader sequence, a coding sequence and a 3′nontranslated sequence, comprising a polyadenylation site. The phrase“expression of a gene” refers to the process wherein a gene istranscribed into an RNA and/or translated into an active protein.

The term “gene of interest” (GOI) is meant to refer to a heterologoussequence introduced into an AAV expression vector, and typically refersto a nucleic acid sequence encoding a protein of therapeutic use inhumans or animals.

The term “herpesvirus” or “herpesviridae family” is meant to refer tothe general family of enveloped, double-stranded DNA viruses withrelatively large genomes. The family replicates in the nucleus of a widerange of vertebrate and invertebrate hosts, in preferred embodiments,mammalian hosts, for example in humans, horses, cattle, mice, and pigs.Exemplary members of the herpesviridae family include cytomegalovirus(CMV), herpes simplex virus types 1 and 2 (HSV1 and HSV2) and varicellazoster (VZV) and epstein ban virus (EBV).

The term “infection” is meant to refer to delivery of heterologous DNAinto a cell by a virus. The term “co-infection” as used herein means“simultaneous infection,” “double infection,” “multiple infection,” or“serial infection” with two or more viruses. Infection of a producercell with two (or more) viruses will be referred to as “co-infection.”The term “transfection” refers to a process of delivering heterologousDNA to a cell by physical or chemical methods, such as plasmid DNA,which is transferred into the cell by means of electroporation, calciumphosphate precipitation, or other methods well known in the art.

The terms “recombinant HSV,” “rHSV,” and “rHSV vector” refer toisolated, genetically modified forms of herpes simplex virus type 1(HSV) containing heterologous genes incorporated into the viral genome.By the term “rHSV-rep2cap2” or “rHSV-rep2cap1” is meant an rHSV in whichthe AAV rep and cap genes from either AAV serotype 1 or 2 have beenincorporated into the rHSV genome. In certain embodiments, a DNAsequence encoding a therapeutic gene of interest has been incorporatedinto the viral genome.

The term “AAV virion” refers to a complete virus particle, such as forexample a wild type AAV virion particle, which comprises single strandedgenome DNA packaged into AAV capsid proteins. The single strandednucleic acid molecule is either sense strand or antisense strand, asboth strands are equally infectious. The term “rAAV viral particle”refers to a recombinant AAV virus particle, i.e. a particle that isinfectious but replication defective. A rAAV viral particle comprisessingle stranded genome DNA packaged into AAV capsid proteins.

The term “therapeutic protein” as used herein refers to a protein, whichhas a therapeutic effect on a disease or disorder to be treated. Thetherapeutic protein, when expressed in an effective amount (or dosage)is sufficient to prevent, correct and/or normalize an abnormalphysiological response. For example, a therapeutic protein may besufficient to reduce by at least about 30 percent, more preferably by atleast 50 percent, most preferably by at least 90 percent, a clinicallysignificant feature of disease or disorder.

As used herein, the term “transgene” refers to a heterologous gene(s),or recombinant genes (“gene cassette”) in a vector, which is transducedinto a cell. Use of the term “transgene” encompasses both introductionof the gene or gene cassette for purposes of correcting a gene defect inthe cell, or altering the functions of the transduced and/or surroundingcells, and introduction of the gene or gene cassette into a producercell for purposes of enabling the cell to produce rAAV. In certainembodiments, introducing the gene or gene cassette for the purposes ofcorrecting a gene defect in the cell or altering the functions of thetransduced and/or surrounding cells can be carried out by gene therapy.By the term “vector” is meant a recombinant plasmid or viral constructused as a vehicle for introduction of transgenes into cells.

Adeno-Associated Virus (AAV)

Adeno-Associated Virus (AAV) is a non-pathogenic single-stranded DNAparvovirus. AAV has a capsid diameter of about 20 nm. Each end of thesingle-stranded DNA genome contains an inverted terminal repeat (ITR),which is the only cis-acting element required for genome replication andpackaging. The AAV genome carries two viral genes: rep and cap. Thevirus utilizes two promoters and alternative splicing to generate fourproteins necessary for replication (Rep78, Rep 68, Rep 52 and Rep 40). Athird promoter generates the transcript for three structural viralcapsid proteins, 1, 2 and 3 (VP1, VP2 and VP3), through a combination ofalternate splicing and alternate translation start codons (Berns K I,Linden R M. The cryptic life style of adeno-associated virus. Bioessays.1995; 17:237-45). The three capsid proteins share the same C-terminal533 amino acids, while VP2 and VP1 contain additional N-terminalsequences of 65 and 202 amino acids, respectively. The AAV virioncontains a total of 60 copies of VP1, VP2, and VP3 at a 1:1:20 ratio,arranged in a T=1 icosahedral symmetry (Rose J A, Maizel J V Jr, Inman JK, Shatkin A J. Structural proteins of adenovirus-associated viruses. JVirol. 1971; 8:766-70). AAV requires Adenovirus (Ad), Herpes SimplexVirus (HSV) or other viruses as a helper virus to complete its lyticlife-cycle (Atchison R W, Casto B C, Hammon W M. Adenovirus-AssociatedDefective Virus Particles. Science. 1965; 149:754-6; Hoggan M D,Blacklow N R, Rowe W P. Studies of small DNA viruses found in variousadenovirus preparations: physical, biological, and immunologicalcharacteristics. Proc Natl Acad Sci USA. 1966; 55:1467-74). In theabsence of the helper virus, wt AAV establishes latency by integrationwith the assistance of Rep proteins through the interaction of the ITRwith the chromosome (Berns et al., 1995).

AAV Serotypes

There are a number of different AAV serotypes, including AAV-1, AAV-2,AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, and AAV-8, AAV-9, and rh-AAV-10. Invivo studies have shown that the various AAV serotypes display differenttissue or cell tropisms. For example, AAV-1 and AAV-6 are two serotypesthat are efficient for the transduction of skeletal muscle (Gao G P,Alvira M R, Wang L, et al. Novel adeno-associated viruses from rhesusmonkeys as vectors for human gene therapy. Proc Natl Acad Sci USA. 2002;99:11854-11859; Xiao W, Chirmule N, Berta S C, et al. Gene therapyvectors based on adeno-associated virus type 1. J Virol. 1999;73:3994-4003; Chao H, Liu Y, Rabinowitz J, et al. Several log increasein therapeutic transgene delivery by distinct adeno-associated viralserotype vectors. Mol Ther. 2000; 2:619-623). AAV-3 has been shown to besuperior for the transduction of megakaryocytes (Handa A, Muramatsu S,Qiu J, Mizukami H, Brown K E. Adeno-associated virus (AAV)-3-basedvectors transduce haematopoietic cells not susceptible to transductionwith AAV-2-based vectors. J Gen Virol. 2000; 81:2077-2084). AAV-5 andAAV-6 infect apical airway cells efficiently (Zabner J, Seiler M,Walters R, et al. Adeno-associated virus type 5 (AAV5) but not AAV2binds to the apical surfaces of airway epithelia and facilitates genetransfer. J Virol. 2000; 74:3852-3858; Halbert C L, Allen J M, Miller AD. Adeno-associated virus type 6 (AAV6) vectors mediate efficienttransduction of airway epithelial cells in mouse lungs compared to thatof AAV2 vectors. J Virol. 2001; 75:6615-6624). AAV-2, AAV-4, and AAV-5transduce different types of cells in the central nervous system(Davidson B L, Stein C S, Heth J A, et al. Recombinant adeno-associatedvirus type 2, 4, and 5 vectors: transduction of variant cell types andregions in the mammalian central nervous system. Proc Natl Acad Sci USA.2000; 97:3428-3432). AAV-8 and AAV-5 can transduce liver cells betterthan AAV-2 (Gao G P, Alvira M R, Wang L, et al. Novel adeno-associatedviruses from rhesus monkeys as vectors for human gene therapy. Proc NatlAcad Sci USA. 2002; 99:11854-11859; Mingozzi F, Schuttrumpf J, Arruda VR, et al. Improved hepatic gene transfer by using an adeno-associatedvirus serotype 5 vector. J Virol. 2002; 76:10497-10502). WO99/61601,incorporated by reference in its entirety herein, shows that AAV5 basedvectors transduced certain cell types (cultured airway epithelial cells,cultured striated muscle cells and cultured human umbilical veinendothelial cells) at a higher efficiency than AAV2, while both AAV2 andAAV5 showed poor transduction efficiencies for NIH 3T3, skbr3 and t-47Dcell lines. AAV-4 was found to transduce rat retina most efficiently,followed by AAV-5 and AAV-1 (Rabinowitz J E, Rolling F, Li C, et al.Cross-packaging of a single adeno-associated virus (AAV) type 2 vectorgenome into multiple AAV serotypes enables transduction with broadspecificity. J Virol. 2002; 76:791-801; Weber M, Rabinowitz J, ProvostN, et al. Recombinant adeno-associated virus serotype 4 mediates uniqueand exclusive long-term transduction of retinal pigmented epithelium inrat, dog, and nonhuman primate after subretinal delivery. Mol Ther.2003; 7:774-781).

Since the development of naturally occurring AAV serotypes into genetherapy vectors, much effort has been focused towards understanding thetropism of each serotype so that further modification to the virus couldbe performed to enhance the efficiency of gene transfer. One approach isto swap domains from one serotype capsid to another, and thus createhybrid vectors with desirable qualities from each parent. As the viralcapsid is responsible for cellular receptor binding, the understandingof viral capsid domain(s) critical for binding is important. Mutationstudies on the viral capsid (mainly on AAV2) performed before theavailability of the crystal structure were mostly based on capsidsurface functionalization by adsorption of exogenous moieties, insertionof peptide at a random position, or comprehensive mutagenesis at theamino acid level. Choi et al. (Curr Gene Ther. 2005 June; 5(3):299-310), incorporated by reference in its entirety herein, describedifferent approaches and considerations for hybrid serotypes.

The invention includes a method for producing rAAV particles with capsidproteins expressed by multiple serotypes of AAV. This is achieved byco-infection of producer cells with a rHSV expression virus and with arHSV-rep2capX helper virus in which the cap gene products are derivedfrom serotypes of AAV other than, or in addition to, AAV2. RecombinantAAV vectors have generally been based on AAV-2 capsids. It has recentlybeen demonstrated that rAAV vectors based on capsids from AAV-1, AAV-3,AAV-4, AAV-5, AAV-8 or AAV-9 serotypes differ from AAV-2 in theirtropism.

Capsids from other AAV serotypes offer advantages in certain in vivoapplications over rAAV vectors based on the AAV-2 capsid. First, theappropriate use of rAAV vectors with particular serotypes may increasethe efficiency of gene delivery in vivo to certain target cells that arepoorly infected, or not infected at all, by AAV-2 based vectors.Secondly, it may be advantageous to use rAAV vectors based on other AAVserotypes if re-administration of rAAV vector becomes clinicallynecessary. It has been demonstrated that re-administration of the samerAAV vector with the same capsid can be ineffective, possibly due to thegeneration of neutralizing antibodies generated to the vector (Xiao, etal., 1999, Halbert, et al., 1997). This problem may be avoided byadministration of a rAAV particle whose capsid is composed of proteinsfrom a different AAV serotype, not affected by the presence of aneutralizing antibody to the first rAAV vector (Xiao, et al., 1999). Forthe above reasons, recombinant AAV vectors constructed using cap genesfrom serotypes including and in addition to AAV-2 are desirable. It willbe recognized that the construction of recombinant HSV vectors similarto rHSV but encoding the cap genes from other AAV serotypes (e.g. AAV-1,AAV-2, AAV-3, AAV-5 to AAV-9) is achievable using the methods describedherein to produce rHSV. In certain preferred embodiments of theinvention as described herein, recombinant AAV vectors constructed usingcap genes from different AAV are preferred. The significant advantagesof construction of these additional rHSV vectors are ease and savings oftime, compared with alternative methods used for the large-scaleproduction of rAAV. In particular, the difficult process of constructingnew rep and cap inducible cell lines for each different capsid serotypesis avoided.

AAV and Gene Therapy

Gene therapy refers to treatment of inherited or acquired diseases byreplacing, altering, or supplementing a gene responsible for thedisease. It is achieved by introduction of a corrective gene or genesinto a host cell, generally by means of a vehicle or vector. Genetherapy using rAAV holds great promise for the treatment of manydiseases. The invention provides a novel method of producing recombinantadeno-associated virus (rAAV), and in particular producing largequantities of recombinant AAV, to support clinical applications.

To date more than 500 gene therapy clinical trials have been conductedworldwide. Efforts to use rAAV as a vehicle for gene therapy holdpromise for its applicability as a treatment for human diseases.Already, some success has been achieved pre-clinically, usingrecombinant AAV (rAAV) for the delivery and long-term expression ofintroduced genes into cells in animals, including clinically importantnon-dividing cells of the brain, liver, skeletal muscle and lung. Insome tissues, AAV vectors have been shown to integrate into the genomeof the target cell (Hirata et al. 2000, J. of Virology 74:4612-4620).

An additional advantage of rAAV is its ability to perform this functionin non-dividing cell types including hepatocytes, neurons and skeletalmyocytes. rAAV has been used successfully as a gene therapy vehicle toenable expression of erythropoietin in skeletal muscle of mice (Kessleret al., 1996), tyrosine hydroxylase and aromatic amino aciddecarboxylase in the CNS in monkey models of Parkinson disease (Kaplittet al., 1994) and Factor IX in skeletal muscle and liver in animalmodels of hemophilia. At the clinical level, the rAAV vector has beenused in human clinical trials to deliver the CFTR gene to cysticfibrosis patients and the Factor IX gene to hemophilia patients (Flotte,et al., 1998, Wagner et al, 1998). Further, AAV is a helper-dependentDNA parvovirus, which is not associated with disease in humans ormammals (Berns and Bohensky, 1987, Advances in Virus Research, AcademicPress Inc, 32:243-307). Accordingly, one of the most importantattributes of AAV vectors is their safety profile in phase I clinicaltrials.

AAV gene therapy has been carried out in a number of differentpathological settings and to treat a various diseases and disorders. Forexample, in a phase I study, administration of an AAV2-FIX vector intothe skeletal muscle of eight hemophilia B subjects proved safe andachieved local gene transfer and Factor IX expression for at least 10months after vector injection (Jiang et al, Mol Ther. 2006 September; 14(3):452-5. Epub 2006 Jul. 5), a phase I trial of intramuscular injectionof a recombinant adeno-associated virus alpha 1-antitrypsin(rAAV2-CB-hAAT) gene vector to AAT-deficient adults has been describedpreviously (Flotte et al., Hum Gene Ther. 2004 January; 15(1):93-128),and in another clinical trial AAV-GAD gene therapy of the subthalamicnucleus has been shown to be safe and well tolerated by patients withadvanced Parkinson's disease (Kaplitt et al. Lancet. 2007 Jun. 23;369(9579):2097-105).

Conventional AAV production methodologies make use of procedures knownto limit the number of rAAV that a single producer cell can make. Thefirst of these is transfection using plasmids for delivery of DNA to thecells. It is well known that plasmid transfection is an inherentlyinefficient process requiring high genome copies and therefore largeamounts of DNA (Hauswirth et al., 2000).

Advances toward achieving the desired goal of scalable productionsystems that can yield large quantities of clinical grade rAAV vectorshave largely been made in production systems that utilize transfectionas a means of delivering the genetic elements needed for rAAV productionin a cell. For example, removal of contaminating adenovirus helper hasbeen circumvented by replacing adenovirus infection with plasmidtransfection in a three-plasmid transfection system in which a thirdplasmid comprises nucleic acid sequences encoding adenovirus helperproteins (Xiao et al. 1998). Improvements in two-plasmid transfectionsystems have also simplified the production process and increased rAAVvector production efficiency (Grimm et al., 1998). Despite theseadvances, it is generally recognized that transfection systems arelimited in their efficiency by the uptake of exogenous DNA, and in theircommercial utility due to scaling difficulties.

Several strategies for improving yields of rAAV from cultured mammaliancells are based on the development of specialized producer cells createdby genetic engineering. In one approach, production of rAAV on a largescale has been accomplished by using genetically engineered “proviral”cell lines in which an inserted AAV genome can be “rescued” by infectingthe cell with helper adenovirus or HSV. Proviral cell lines can berescued by simple adenovirus infection, offering increased efficiencyrelative to transfection protocols. However, as with the earliertransfection methods, adenovirus is introduced into the system that mustlater be removed. Additionally, the rAAV yield is generally low inproviral cell lines (Qiao et al. 2002a). There are several furtherdisadvantages that limit approaches using proviral cell lines. The cellcloning and selection process itself can be laborious; additionally,this process must be carried out to generate a unique cell line for eachtherapeutic gene of interest (GOI). Furthermore, cell clones havinginserts of unpredictable stability can be generated from proviral celllines.

A second cell-based approach to improving yields of rAAV from cellsinvolves the use of genetically engineered “packaging” cell lines thatharbor in their genomes either the AAV rep and cap genes, or both therep-cap and the ITR-gene of interest (Qiao et al., 2002b). In the formerapproach, in order to produce rAAV, a packaging cell line is eitherinfected or transfected with helper functions, and with the AAV ITR-GOIelements. The latter approach entails infection or transfection of thecells with only the helper functions. Typically, rAAV production using apackaging cell line is initiated by infecting the cells with wild-typeadenovirus, or recombinant adenovirus. Because the packaging cellscomprise the rep and cap genes, it is not necessary to supply theseelements exogenously.

While rAAV yields from packaging cell lines have been shown to be higherthan those obtained by proviral cell line rescue or transfectionprotocols, packaging cell lines typically suffer from recombinationevents, such as recombination of E1a-deleted adenovirus vector with host293 cell DNA. Infection with recombinant adenovirus therefore initiatesboth rAAV production and generation of replication-competent adenovirus.Furthermore, only limited success has been achieved in creatingpackaging cell lines with stable genetic inserts.

Recent progress in improving yields of rAAV has also been made usingapproaches based on delivery of helper functions from herpes simplexvirus (HSV) using recombinant HSV amplicon systems. Although modestlevels of rAAV vector yield, of the order of 150-500 viral genomes (vg)per cell, were initially reported (Conway et al., 1997), more recentimprovements in rHSV amplicon-based systems have provided substantiallyhigher yields of rAAV v.g. and infectious particles (ip) per cell(Feudner et al., 2002). Amplicon systems are inherentlyreplication-deficient; however the use of a “gutted” vector,replication-competent (rcHSV), or replication-deficient rHSV stillintroduces immunogenic HSV components into rAAV production systems.Therefore, appropriate assays for these components and correspondingpurification protocols for their removal must be implemented.Additionally, amplicon stocks are difficult to generate in high titer,and often contain substantial parental virus contamination.

It is apparent from the foregoing that there is a clear need forimproved large-scale methods for production of high titer, rAAV toovercome the major barrier to the routine use of rAAV for gene therapy.The current invention provides methods for producing clinically relevantrecombinant AAV viral particles using mammalian cells capable of growingin suspension.

METHODS OF THE INVENTION

Various embodiments of the present invention involve methods forproducing recombinant AAV viral particles in a mammalian cell. Themethods as described comprise in certain embodiments co-infecting amammalian cell capable of growing in suspension with a first recombinantherpesvirus comprising a nucleic acid sequence encoding an AAV rep andan AAV cap gene each operably linked to a promoter, and a secondrecombinant herpesvirus comprising a gene of interest, and a promoteroperably linked to said gene of interest, flanked by AAV invertedterminal repeats to facilitate packaging of the gene of interest, andallowing the virus to infect the mammalian cell, thereby producingrecombinant AAV viral particles in a mammalian cell.

Any type of mammalian cell that is capable of supporting replication ofherpesvirus is suitable for use according to the methods of theinvention as described herein. Accordingly, the mammalian cell can beconsidered a host cell for the replication of herpesvirus as describedin the methods herein. Any cell type for use as a host cell iscontemplated by the present invention, as long as the cell is capable ofsupporting replication of herpesvirus. Examples of suitable geneticallyunmodified mammalian cells include but are not limited to cell linessuch as HEK-293 (293), Vero, RD, BHK-21, HT-1080, A549, Cos-7, ARPE-19,and MRC-5. One of skill in the art would be familiar with the wide rangeof host cells that are available for use in methods for producing anrAAV, in particular examples a rAAV as described in the embodimentsherein.

The host cells used in the various embodiments of the present inventionmay be derived, for example, from mammalian cells such as humanembryonic kidney cells or primate cells. Other cell types might include,but are not limited to BHK cells, Vero cells, CHO cells or anyeukaryotic cells for which tissue culture techniques are established aslong as the cells are herpesvirus permissive. The term “herpesviruspermissive” means that the herpesvirus or herpesvirus vector is able tocomplete the entire intracellular virus life cycle within the cellularenvironment. In certain embodiments, methods as described occur in themammalian cell line BHK, growing in suspension.

The host cell may be derived from an existing cell line, e.g., from aBHK cell line, or developed de novo.

US Application No. 20070172846, incorporated by reference in itsentirety herein, describes methodologies that have been used to adapt293 cells into suspension cultures. Graham adapted 293A cells intosuspension culture (293N3S cells) by 3 serial passages in nude mice(Graham, J. Gen. Virol., 68(Pt 3):937-940, 1987). The suspension 293N3Scells were found to be capable of supporting the replication ofE1-deleted adenoviral vectors. However, Garnier et al. (Garnier et al.,Cytotechnology, 15(1-3):145-155, 1994) observed that the 293N35 cellshad a relatively long initial lag phase in suspension, a low growthrate, and a strong tendency to clump.

A second method that has been used is a gradual adaptation of 293A cellsinto suspension growth (Cold Spring Harbor Laboratories, 293S cells).Garnier et al. (1994) reported the use of 293S cells for production ofrecombinant proteins from adenoviral vectors. The authors found that293S cells were much less clumpy in calcium-free media and a freshmedium exchange at the time of virus infection could significantlyincrease the protein production. It was found that glucose was thelimiting factor in culture without medium exchange.

The methods of the invention include also a recombinant AAV viralparticle produced in a mammalian cell by the method comprisingco-infecting a mammalian cell capable of growing in suspension with afirst recombinant herpesvirus comprising a nucleic acid encoding an AAVrep and an AAV cap gene each operably linked to a promoter; and (ii) asecond recombinant herpesvirus comprising a gene of interest, and apromoter operably linked to said gene of interest; and allowing thevirus to infect the mammalian cell, and thereby producing recombinantAAV viral particles in a mammalian cell. As described herein, theherpesvirus is a virus selected from the group consisting of:cytomegalovirus (CMV), herpes simplex (HSV) and varicella zoster (VZV)and epstein barr virus (EBV). The recombinant herpesvirus is replicationdefective. The AAV cap gene has a serotype selected from the groupconsisting of AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8,AAV-9, and rhAAV-10.

As described in greater detail in other parts of the application, therecombinant viral particle described herein, wherein the gene ofinterest is a therapeutic gene, that can be, but is in no way limitedto, a gene is selected from the group consisting of: anti-angiogenicgenes, alpha-1 antitrypsin, retinoschisin, acid alpha glucosidase,RPE65, beta-subunit of the cone photoreceptor cGMP-gated channel(CNGB-3), alpha-subunit of the cone photoreceptor cGMP-gated channel(CNGA-3), cone photoreceptor G-protein alpha-subunit (GNAT2), Retinalpigment epithelium-specific 65 kDa (RPE65), X-linked juvenileretinoschisis (RS1), Brain-derived neurotrophic factor (BDNF), Glialcell-derived neurotrophic factor (GDNF), Myotonic dystrophy proteinkinase (DMPK), CCHC-type zinc finger, nucleic acid binding protein(known as CNBP or ZNF9), Retinitis pigmentosa GTPase regulator (RPGR),Acid α-glucosidase (GAA), Choroideremia (CHM), Rab escort protein-1(REP1), Alpha-synuclein (SNCA), Coagulation factor VIII, procoagulantcomponent (hemophilia A or F8), Coagulation factor IX (plasmathromboplastic component, Christmas disease, hemophilia B or F9), Arylhydrocarbon receptor interacting protein-like 1 (AIPL1), X-linkedInhibitor of Apoptosis Protein (XIAP), clarin-1 (CLRN1), Leber'shereditary neuropathy genes (MT-ND1, MT-ND4, MT-ND4L, and MT-ND6),alpha-galactosidase A (α-Gal A) or Alpha-L-iduronidase.

Diseases to be Treated

In embodiments of the instant invention where the method for producingrecombinant AAV viral particles in a mammalian cell comprisesco-infecting a mammalian cell capable of growing in suspension with afirst recombinant herpesvirus and a second recombinant herpesviruscomprising a gene of interest, the invention contemplates use of anygene that has therapeutic or potential therapeutic value in thetreatment of a disease or genetic disorder. One of skill in the artwould be familiar with the wide range of such genes that have beenidentified.

In certain embodiments, the therapeutic genes involved may be those thatencode proteins, structural or enzymatic RNAs, inhibitory products suchas antisense RNA or DNA, or any other gene product. Expression is thegeneration of such a gene product or the resultant effects of thegeneration of such a gene product. Thus, enhanced expression includesthe greater production of any therapeutic gene or the augmentation ofthat product's role in determining the condition of the cell, tissue,organ, or organism.

In certain embodiments, the therapeutic gene may encode one or moreanti-angiogenic proteins.

For example, the therapeutic gene can be, but is not limited to anantisense gene, for example antisense ras, antisense myc, antisense raf,antisense erb, antisense src, antisense fms, antisense jun, antisensetrk, antisense ret, antisense gsp, antisense hst, antisense bcl,antisense abl, Rb, CFTR, p16, p21, p27, p57, p′73, C-CAM, APC, CTS-1,zac1, scFV ras, DCC, NF-1, NF-2, WT-1, MEN-I, MEN-II, BRCA1, VHL, MMAC1,FCC, MCC, BRCA2, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9,IL-10, IL-11 IL-12, GM-CSF, G-CSF, thymidine kinase, mda7, fus-1,interferon .alpha., interferon .beta., interferon .gamma., ADP, p53,ABLI, BLC1, BLC6, CBFA1, CBL, CSFIR, ERBA, ERBB, EBRB2, ETS1, ETS2,ETV6, FGR, FOX, FYN, HCR, HRAS, JUN, KRAS, LCK, LYN, MDM2, MLL, MYB,MYC, MYCL1, MYCN, NRAS, PIM1, PML, RET, SRC, TALI, TCL3, YES, MADH4,RB1, TP53, WT1, TNF, BDNF, CNTF, NGF, IGF, GMF, aFGF, bFGF, NT3, NT5,ApoAI, ApoAIV, ApoE, Rap1A, cytosine deaminase, Fab, ScFv, BRCA2, zac1,ATM, HIC-1, DPC-4, FHIT, PTEN, ING1, NOEY1, NOEY2, OVCA1, MADR2, 53BP2,IRF-1, Rb, zac1, DBCCR-1, rks-3, COX-1, TFPI, PGS, Dp, E2F, ras, myc,neu, raf, erb, fms, trk, ret, gsp, hst, abl, E1A, p300, VEGF, FGF,thrombospondin, BAI-1, GDAIF, or MCC. In further embodiments of thepresent invention, the recombinant gene is a gene encoding an ACPdesaturase, an ACP hydroxylase, an ADP-glucose pyrophorylase, an ATPase,an alcohol dehydrogenase, an alpha 1 antitrypsin gene, an amylase, anamyloglucosidase, a catalase, a cellulase, a cyclooxygenase, adecarboxylase, a dextrinase, an esterase, a DNA polymerase, an RNApolymerase, FLt01, a hyaluron synthase, a galactosidase, a glucanase, aglucose oxidase, a GTPase, a helicase, a hemicellulase, a hyaluronidase,an integrase, an invertase, an isomerase, a kinase, a lactase, a lipase,a lipoxygenase, a lyase, a lysozyme, a pectinesterase, a peroxidase, aphosphatase, a phospholipase, a phosphorylase, a polygalacturonase, aproteinase, a peptidease, a pullanase, a recombinase, a reversetranscriptase, a topoisomerase, a xylanase, a reporter gene, aninterleukin, or a cytokine. In other embodiments of the presentinvention, the recombinant gene is a gene encoding carbamoyl synthetaseI, ornithine transcarbamylase, arginosuccinate synthetase,arginosuccinate lyase, arginase, fumarylacetoacetate hydrolase,phenylalanine hydroxylase, alpha-1 antitrypsin, glucose-6-phosphatase,low-density-lipoprotein receptor, porphobilinogen deaminase, factorVIII, factor IX, cystathione .beta.-synthase, branched chain ketoaciddecarboxylase, albumin, isovaleryl-CoA dehydrogenase, propionyl CoAcarboxylase, methyl malonyl CoA mutase, glutaryl CoA dehydrogenase,insulin, beta.-glucosidase, pyruvate carboxylase, hepatic phosphorylase,phosphorylase kinase, glycine decarboxylase, H-protein, T-protein,Menkes disease copper-transporting ATPase, Wilson's diseasecopper-transporting ATPase, cytosine deaminase, hypoxanthine-guaninephosphoribosyltransferase, galactose-1-phosphate uridyltransferase,phenylalanine hydroxylase, glucocerbrosidase, sphingomyelinase,.alpha.-L-iduronidase, glucose-6-phosphate dehydrogenase, HSV thymidinekinase, or human thymidine kinase. Alternatively, the recombinant genemay encode growth hormone, prolactin, placental lactogen, luteinizinghormone, follicle-stimulating hormone, chorionic gonadotropin,thyroid-stimulating hormone, leptin, adrenocorticotropin, angiotensin I,angiotensin II, beta.-endorphin, .beta.-melanocyte stimulating hormone,cholecystokinin, endothelin I, galanin, gastric inhibitory peptide,glucagon, insulin, lipotropins, neurophysins, somatostatin, calcitonin,calcitonin gene related peptide, beta-calcitonin gene related peptide,hypercalcemia of malignancy factor, parathyroid hormone-related protein,parathyroid hormone-related protein, glucagon-like peptide,pancreastatin, pancreatic peptide, peptide YY, PHM, secretin, vasoactiveintestinal peptide, oxytocin, vasopressin, vasotocin, enkephalinamide,metorphinamide, alpha melanocyte stimulating hormone, atrial natriureticfactor, amylin, amyloid P component, corticotropin releasing hormone,growth hormone releasing factor, luteinizing hormone-releasing hormone,neuropeptide Y, substance K, substance P, or thyrotropin releasinghormone.

In other embodiments, the therapeutic gene of the invention isanti-angiogenic genes, alpha-1 antitrypsin, retinoschisin, acid alphaglucosidase, RPE65, beta-subunit of the cone photoreceptor cGMP-gatedchannel (CNGB-3), alpha-subunit of the cone photoreceptor cGMP-gatedchannel (CNGA-3), cone photoreceptor G-protein alpha-subunit (GNAT2),Retinal pigment epithelium-specific 65 kDa (RPE65), X-linked juvenileretinoschisis (RS1), Brain-derived neurotrophic factor (BDNF), Glialcell-derived neurotrophic factor (GDNF), Myotonic dystrophy proteinkinase (DMPK), CCHC-type zinc finger, nucleic acid binding protein(known as CNBP or ZNF9), Retinitis pigmentosa GTPase regulator (RPGR),Acid α-glucosidase (GAA), Choroideremia (CHM), Rab escort protein-1(REP1), Alpha-synuclein (SNCA), Coagulation factor VIII, procoagulantcomponent (hemophilia A or F8), Coagulation factor IX (plasmathromboplastic component, Christmas disease, hemophilia B or F9), Arylhydrocarbon receptor interacting protein-like 1 (AIPL1), X-linkedInhibitor of Apoptosis Protein (XIAP), clarin-1 (CLRN1), Leber'shereditary neuropathy genes (MT-ND1, MT-ND4, MT-ND4L, and MT-ND6),alpha-galactosidase A (α-Gal A) or Alpha-L-iduronidase.

In certain preferred embodiments of the invention, the therapeutic geneof interest is an angiogenesis inhibition gene (AI) or an alpha 1antitrypsin gene (AAT).Production Technologies for rAAV

U.S. application Ser. No. 11/503,775, incorporated by reference in itsentirety herein, describes required elements of rAAV Production Systems.Recombinant AAV is produced in vitro by introduction of gene constructsinto cells known as producer cells. Known systems for production of rAAVemploy three fundamental elements: 1) a gene cassette containing thegene of interest, 2) a gene cassette containing AAV rep and cap genesand 3) a source of “helper” virus proteins.

The first gene cassette is constructed with the gene of interest flankedby inverted terminal repeats (ITRs) from AAV. ITRs function to directintegration of the gene of interest into the host cell genome and areessential for encapsidation of the recombinant genome. (Hermonat andMuzyczka, 1984, Samulski, et al., 1983). The second gene cassettecontains rep and cap, AAV genes encoding proteins needed for replicationand packaging of rAAV. The rep gene encodes four proteins (Rep 78, 68,52 and 40) required for DNA replication. The cap genes encode threestructural proteins (VP1, VP2, and VP3) that make up the virus capsid(Muzyczka and Berns, 2001.)

The third element is required because AAV does not replicate on its own.Helper functions are protein products from helper DNA viruses thatcreate a cellular environment conducive to efficient replication andpackaging of rAAV. Traditionally, adenovirus (Ad) has been used toprovide helper functions for rAAV, but herpesviruses can also providethese functions as discussed below.

Production of rAAV vectors for gene therapy is carried out in vitro,using suitable producer cell lines such as BHK cells grown insuspension. Other cell lines suitable for use in the invention includeHEK-293 (293), Vero, RD, BHK-21, HT-1080, A549, Cos-7, ARPE-19, andMRC-5.

Any cell type can be used as a host cell, as long as the cell is capableof supporting replication of a herpesvirus. One of skill in the artwould be familiar with the wide range of host cells that can be used inthe production of herpesvirus from host cells. Examples of suitablegenetically unmodified mammalian host cells, for example, may includebut are not limited to cell lines such as HEK-293 (293), Vero, RD,BHK-21, HT-1080, A549, Cos-7, ARPE-19, and MRC-5.

In particular embodiments, a host cell is adapted for growth insuspension culture. In certain embodiments of the present invention, thehost cells are Baby Hamster Kidney (BHK) cells. BHK cell line grown insuspension is derived from an adaptation of the adherent BHK cell line.Both cell lines are available commercially.

A well known strategy for delivering all of the required elements forrAAV production utilizes two plasmids and a helper virus. This methodrelies on transfection of the producer cells with plasmids containinggene cassettes encoding the necessary gene products, as well asinfection of the cells with Ad to provide the helper functions. Thissystem employs plasmids with two different gene cassettes. The first isa proviral plasmid encoding the recombinant DNA to be packaged as rAAV.The second is a plasmid encoding the rep and cap genes. To introducethese various elements into the cells, the cells are infected with Ad aswell as transfected with the two plasmids. The gene products provided byAd are encoded by the genes E1a, E1b, E2a, E4orf6, and Va (Samulski etal., 1998; Hauswirth et al., 2000; Muzyczka and Burns, 2001).Alternatively, in more recent protocols, the Ad infection step can bereplaced by transfection with an adenovirus “helper plasmid” containingthe VA, E2A and E4 genes (Xiao, et al., 1998, Matsushita, et al., 1998).

While Ad has been used conventionally as the helper virus for rAAVproduction, it is known that other DNA viruses, such as herpes simplexvirus type 1 (HSV-1) can be used as well. The minimal set of HSV-1 genesrequired for AAV2 replication and packaging has been identified, andincludes the early genes UL5, UL8, UL52 and UL29 (Muzyczka and Burns,2001). These genes encode components of the HSV-1 core replicationmachinery, i.e., the helicase, primase, primase accessory proteins, andthe single-stranded DNA binding protein (Knipe, 1989; Weller, 1991).This rAAV helper property of HSV-1 has been utilized in the design andconstruction of a recombinant herpes virus vector capable of providinghelper virus gene products needed for rAAV production (Conway et al.,1999).

Production of rAAV vectors for gene therapy is carried out in vitro,using suitable producer cell lines such as BHK cells grown insuspension. Other cell lines suitable for use in the invention includeHEK-293 (293), Vero, RD, BHK-21, HT-1080, A549, Cos-7, ARPE-19, andMRC-5.

Any cell type can be used as a host cell, as long as the cell is capableof supporting replication of a herpesvirus. One of skill in the artwould be familiar with the wide range of host cells that can be used inthe production of herpesvirus from host cells. Examples of suitablegenetically unmodified mammalian host cells, for example, may includebut are not limited to cell lines such as HEK-293 (293), Vero, RD,BHK-21, HT-1080, A549, Cos-7, ARPE-19, and MRC-5.

In particular embodiments, a host cell is adapted for growth insuspension culture. In certain embodiments of the present invention, thehost cells are Baby Hamster Kidney (BHK) cells. BHK cell line grown insuspension is derived from an adaptation of the adherent BHK cell line.Both cell lines are available commercially.

rHSV-Based rAAV Manufacturing Process

The instant invention provides production of recombinant AAV viralparticles in cells growing in suspension. Suspension or non-anchoragedependent cultures from continuous established cell lines are the mostwidely used means of large scale production of cells and cell products.Large scale suspension culture based on fermentation technology hasclear advantages for the manufacturing of mammalian cell products. Theprocesses are relatively simple to operate and straightforward to scaleup. Homogeneous conditions can be provided in the bioreactor whichallows for precise monitoring and control of temperature, dissolvedoxygen, and pH, and ensure that representative samples of the culturecan be taken. The rHSV vectors used are readily propagated to high titeron permissive cell lines both in tissue culture flasks and bioreactors,and provided a production protocol amenable to scale-up for virusproduction levels necessary for clinical and market production.

Cell culture in stirred tank bioreactors provides very highvolume-specific culture surface area and has been used for theproduction of viral vaccines (Griffiths, 1986). Furthermore, stirredtank bioreactors have industrially been proven to be scalable. Oneexample is the multiplate CELL CUBE cell culture system. The ability toproduce infectious viral vectors is increasingly important to thepharmaceutical industry, especially in the context of gene therapy.

As used herein, a “bioreactor” refers to any apparatus that can be usedfor the purpose of culturing cells. Growing cells according to thepresent invention in a bioreactor allows for large scale production offully biologically-active cells capable of being infected by the Herpesvectors of the present invention.

Bioreactors have been widely used for the production of biologicalproducts from both suspension and anchorage dependent animal cellcultures. Most large-scale suspension cultures are operated as batch orfed-batch processes because they are the most straightforward to operateand scale up. However, continuous processes based on chemostat orperfusion principles are available.

The bioreactor system can, in certain embodiments, be set up to includea system to allow for media exchange. For example, filters may beincorporated into the bioreactor system to allow for separation of cellsfrom spent media to facilitate media exchange. In some embodiments ofthe present methods for producing Herpes virus, media exchange andperfusion is conducted beginning on a certain day of cell growth. Forexample, media exchange and perfusion can begin on day 3 of cell growth.The filter may be external to the bioreactor, or internal to thebioreactor.

EXAMPLES

It should be appreciated that the invention should not be construed tobe limited to the examples that are now described; rather, the inventionshould be construed to include any and all applications provided hereinand all equivalent variations within the skill of the ordinary artisan.

Example 1 Materials and Methods of the Invention

The invention was performed using the following methods. The methods asdescribed herein are described in the PCT application filed on Aug. 8,2007 (Application No. not yet assigned), entitled Recombinant AAVProduction in Mammalian Cells, which claims the benefit of U.S.application Ser. No. 11/503,775, entitled Recombinant AAV Production inMammalian Cells, filed Aug. 14, 2007, which is a continuation-in-part ofU.S. application Ser. No. 10/252,182, entitled High Titer RecombinantAAV Production, filed Sep. 23, 2002, now U.S. Pat. No. 7,091,029, issuedAug. 15, 2006. The contents of all the aforementioned applications arehereby incorporated by reference in their entirety.

rHSV Co-Infection Method

The rHSV co-infection method for recombinant adeno-associated virus(rAAV) production employs two ICP27-deficient recombinant herpes simplexvirus type 1 (rHSV-1) vectors, one bearing the AAV rep and cap genes(rHSV-rep2capX, with “capX” referring to any of the AAV serotypes), andthe second bearing the gene of interest (GOI) cassette flanked by AAVinverted terminal repeats (ITRs). Although the system was developed withAAV serotype 2 rep, cap, and ITRs, as well as the humanized greenfluorescent protein gene (GFP) as the transgene, the system can beemployed with different transgenes and serotype/pseudotype elements.

Mammalian cells are infected with the rHSV vectors, providing all cisand trans-acting rAAV components as well as the requisite helperfunctions for productive rAAV infection. Cells are infected with amixture of rHSV-rep2capX and rHSV-GOI. Cells are harvested and lysed toliberate rAAV-GOI, and the resulting vector stock is titered by thevarious methods described below.

DOC-Lysis

At harvest, cells and media are separated by centrifugation. The mediais set aside while the cell pellet is extracted with lysis buffer (20 mMTris-HCl, pH 8.0, 150 mM NaCl) containing 0.5% (w/v) deoxycholate (DOC)using 2 to 3 freeze-thaw cycles, which extracts cell-associated rAAV. Insome instances, the media and cell-associated rAAV lysate is recombined.

In Situ Lysis

An alternative method for harvesting rAAV is by in situ lysis. At thetime of harvest, MgCl₂ is added to a final concentration of 1 mM, 10%(v/v) Triton X-100 added to a final concentration of 1% (v/v), andBenzonase is added to a final concentration of 50 units/mL. This mixtureis either shaken or stirred at 37° C. for 2 hours.

Quantitative Real-Time PCR to Determine DRP Yield

The DNAse-resistant particle (DRP) assay employs sequence-specificoligonucleotide primers and a dual-labeled hybridizing probe fordetection and quantification of the amplified DNA sequence usingreal-time quantitative polymerase chain reaction (qPCR) technology. Thetarget sequence is amplified in the presence of a fluorogenic probewhich hybridizes to the DNA and emits a copy-dependent fluorescence. TheDRP titer (DRP/mL) is calculated by direct comparison of relativefluorescence units (RFUs) of the test article to the fluorescent signalgenerated from known plasmid dilutions bearing the same DNA sequence.The data generated from this assay reflect the quantity of packagedviral DNA sequences, and are not indicative of sequence integrity orparticle infectivity.

Green-Cell Infectivity Assay to Determine Infectious Particle Yield(rAAV-GFP Only)

Infectious particle (ip) titering is performed on stocks of rAAV-GFPusing a green cell assay. C12 cells (a HeLa derived line that expressedAAV2 Rep and Cap genes—see references below) are infected with serialdilutions of rAAV-GFP plus saturating concentrations of adenovirus (toprovide helper functions for AAV replication). After two to three daysincubation, the number of fluorescing green cells (each cellrepresenting one infectious event) are counted and used to calculate theip/mL titer of the virus sample.

Clark K R et al. described recombinant adenoviral production in Hum.Gene Ther. 1995. 6:1329-1341 and Gene Ther. 1996. 3:1124-1132, both ofwhich are incorporated by reference in their entireties herein.

TCID₅₀ to Determine rAAV Infectivity

Infectivity of rAAV particles harboring a gene of interest (rAAV-GOI)was determined using a tissue culture infectious dose at 50% (TCID₅₀)assay. Eight replicates of rAAV were serially diluted in the presence ofhuman adenovirus type 5 and used to infect HeLaRC32 cells (aHeLa-derived cell line that expresses AAV2 rep and cap, purchased fromATCC) in a 96-well plate. At three days post-infection, lysis buffer(final concentrations of 1 mM Tris-HCl pH 8.0, 1 mM EDTA, 0.25% (w/v)deoxycholate, 0.45% (v/v) Tween-20, 0.1% (w/v) sodium dodecyl sulfate,0.3 mg/mL Proteinase K) was added to each well then incubated at 37° C.for 1 h, 55° C. for 2 h, and 95° C. for 30 min. The lysate from eachwell (2.5 μL aliquot) was assayed in the DRP qPCR assay described above.Wells with Ct values lower than the value of the lowest quantity ofplasmid of the standard curve were scored as positive. TCID₅₀infectivity per mL (TCID₅₀/mL) was calculated based on the Kärberequation using the ratios of positive wells at 10-fold serial dilutions.

Cell Lines and Viruses

Production of rAAV vectors for gene therapy is carried out in vitro,using suitable producer cell lines such as BHK cells grown insuspension. Other cell lines suitable for use in the invention includeHEK-293 (293), Vero, RD, BHK-21, HT-1080, A549, Cos-7, ARPE-19, andMRC-5.

Mammalian cell lines were maintained in Dulbecco's modified Eagle'smedium (DMEM, Hyclone) containing 2-10% (v/v) fetal bovine serum (FBS,Hyclone) unless otherwise noted. Cell culture and virus propagation wereperformed at 37° C., 5% CO2 for the indicated intervals.

Cell Seeding Density

Host cell suspension stocks, such as BHK suspension cell stock, may beused to seed spinner flasks, shaker flasks, bioreactors or othercultures at various seeding densities. Satisfactory cell growth may beachieved with a wide range of cell seeding densities. For optimal cellgrowth the cell seeding density is recommended to be at least about, atmost about, about, or higher than 2×10⁵ cells/mL and includes, but isnot limited to cell densities of at least about, at most about, or about5×10⁵ cells/mL, including all values or ranges there between.

Culture Temperature

Cells can be cultured at temperatures that include, but are not limitedto at least about, at most about, or about 32.degree. C., 33.degree. C.,34.degree. C., 35.degree. C., 36.degree. C., 37.degree. C., 38.degree.C., 39.degree. C. or 40.degree. C., including all values there between.In certain aspects of the invention the incubation temperature forgrowth of BHK suspension cells will be 37 degree C.

CO₂ Percentage

Cells may be cultured in spinner flasks inside incubators or inbioreactors having an atmosphere of at least about, at most about, orabout 0, 5, 10, 15, or 20% CO₂. In certain preferred embodiments, cellgrowth was achieved at CO₂ percentages of 5% CO₂. Typically, the growthof suspension cells requires CO₂ in the culture environment and shouldbe maintained between 4 and 6 percent or any value or range therebetween.

Cell Growth in Spinner Flask or Bioreactor

In certain embodiments, a spinner flask may be used and seeded withsuspension cells at an appropriate cell seeding density as describedherein. In other certain embodiments, a bioreactor may be used such as aWave disposable bioreactor or a continuous stirred-tank bioreactor) andseeded with suspension cells at an appropriate cell seeding density.Cells are grown inside the spinner flask or bioreactor.

When cells reach a density between 9×10⁵ and 2.5×10⁶ cells/mL, nutrientscan be replenished and waste byproducts removed by media exchange,dilution, or perfusion (continuous media input and removal).Alternatively, the cells can be kept at the higher density to grow cellsto the density desired for rAAV production, in either a spinner flask orbioreactor. Accordingly, a high cell concentration is expected, incertain preferred embodiments, to improve the volumetric productivity ofrecombinant AAV production.

The bioreactor can hold any volume of media, for example a 10 L Wavebioreactor can hold up to 5 L working volume). In certain embodiments,the bioreactor can be adjusted to rock at a particular speed and angle.In certain other embodiments, the bioreactor may include a device formonitoring dissolved oxygen tension, such as a disposable dissolvedoxygen tension (DOT) probe. The bioreactor may also include a device formonitoring temperature in the media. Other embodiments include a devicefor measuring and adjusting culture pH, such as a gas mixer which canadjust CO.sub.2 gas percentage delivered to the media. The bioreactormay or may not be a disposable bioreactor.

Multiplicity of Infection (MOI)

Cells can be infected with recombinant herpesviruses at a combined MOIof between 3 and 14 plaque forming units per cell (pfu/cell). Arelatively consistent virus yield is observed with a combined MOI at orabove 6 pfu/cell. Data suggest that combined MOIs between 6 and 14pfu/cell appear to be the optimal range for rAAV production in BHKsuspension culture.

In preferred embodiments, the invention requires co-infection of cellswith a replication-deficient rHSV vector that provides helper functionsfor rAAV production. The invention provides a simplified rHSV-basedsystem for rAAV production that uses two or more replication-deficientrHSV vectors including one for the delivery of the rAAV rep and capfunctionalities and one for delivery of the therapeutic gene (the geneof interest). Advantageously, the availability of separatereplication-defective rHSV vectors of the invention as described makesit possible to modulate the rep and cap functionalities relative to thegene of interest, by varying the co-infection MOI. The optimal ratio is2:1, but rAAV production can occur with ratios of 1:2 to 6:1 ofrHSV-rep2capX and rHSV-GOI, respectively.

Infection Cell Density

Cells can be grown to various concentrations including, but not limitedto at least about, at most about, or about 1×10⁶ to 4×10⁶ cells/mL. Thecells can then be infected with recombinant herpesvirus at apredetermined MOI.

Media Nutrient Level

In certain embodiments of the invention, the conditions of infectioncomprise media exchange on or about, but not limited to 2 hourspost-infection. Fresh media is preferably, but not limited to,Dulbecco's modified Eagle's medium (DMEM, Hyclone) lacking FBS.

rHSV-1 Vector Construction and Production

A rHSV-rep2cap2 (originally denoted d27.1-rc) was constructed aspreviously described. Briefly, rHSV-rep2cap2 was constructed byhomologous recombination of an AAV2 rep and cap gene cassette into thetk locus of the rHSV-1, ICP27-deleted d27.1 vector in which the AAV2 repand cap genes are under control of their native promoters (p5, p19 andp40). The rHSV-rep2cap1 vector was constructed by as described aboveusing cap1. In this method, any combination of rep and cap can be used.

The rHSV-AAV2/GFP vector (referred to as rHSV-GFP) was constructed byhomologous recombination of a CMV promoter-driven hGFP-neomycinresistance gene cassette, flanked by the AAV2 ITRs, into the tk locus ofthe d27.1 vector as described above.

In certain embodiments, it may be useful to employ selection systemsthat preclude growth of undesirable cells. This may be accomplished byvirtue of permanently transforming a cell line with a selectable markeror by transducing or infecting a cell line with a viral vector thatencodes a selectable marker. In either situation, culture of thetransformed/transduced cell with an appropriate drug or selectivecompound will result in the enhancement, in the cell population, ofthose cells carrying the marker.

The rHSV-rep2capX and rHSV-GOI vectors were propagated on theICP27-complementing cell line V27. V27 is an ICP27-expressing Vero cellline derivative which harbors approximately one copy of the ICP27 geneper haploid genome equivalent. Infection steps were done in the absenceof serum. Vector stocks were propagated either by seeding T225 flaskswith 3×10⁷ V27 cells, or 10-stack cell factories with 1.5×10⁹ V27 cells,followed by infecting 24 h post-seeding with either rHSV-rep2capX orrHSV-GOI at a MOI of 0.15. rHSV vectors were harvested at 72 hourspost-infection (h.p.i.) by separating the infected cells from the mediacentrifugation (10 min, 4° C., 1100 g). The supernatant is set asidewhile the cell pellet is treated with 0.6 M NaCl in 1×Phosphate-buffered saline, pH 6.5, for 30 minutes at 37° C. The cellsare then re-pelleted by centrifugation as above. This second supernatantis recombined with the first supernatant (with the cell pelletdiscarded), formulated with 5% (v/v) sterile glycerol and was stored at−80° C. rHSV-1 vector stocks were used for rAAV production withoutfurther manipulation.

Example 2 Suspension BHK (sBHK) Cell Propagation and Characterization,and Production of rAAV2 in Suspension BHK Cells

rAAV Production in Two Clones of sBHK

Numerous cell lines are capable of producing high specific yields ofrecombinant adeno-associated virus (rAAV) vectors using the rHSVco-infection method, as described in U.S. application Ser. No.11/503,775, which is a continuation-in-part of U.S. application Ser. No.10/252,182, now U.S. Pat. No. 7,091,029, issued Aug. 15, 2006, both ofwhich are incorporated by reference herein. Baby hamster kidney cellsclone 13 (BHK-21) and human embryonic kidney cells (HEK 293) produce thehighest levels of rAAV particularly in comparison to traditional methodsof rAAV production (as described in U.S. application Ser. No.11/503,775, above). Large quantities of recombinant AAV vector arerequired for clinical application, however, the adherent nature of thesecells is an impediment to large scale production. Therefore, cells thatgrow in suspension offer an economic and process advantage for rAAVproduction. In this example, two independent isolates of BHK-21 cellsselected to grow in suspension were analyzed for rAAV production usingthe rHSV co-infection method. Cells were cultured in spinner flasksaccording to recommended guidelines (maintenance between 2×10⁵ and1.3×10⁶ cells/mL) and were co-infected with rHSV-rep2cap2 and rHSV-GFPat a multiplicity of infection (MOI) of 12 and 2. Starting 24 hours postinfection (hpi), samples of the infected cultures were taken at 24 hourintervals. Cells were processed using the DOC-lysis method (seeMethods). Specific yields of infectious particles (ip) per cell(ip/cell) were determined by the green-cell infectivity assay. Thecombined yield of cell-associated and released (media) rAAV2-GFP foreach suspension BHK (sBHK) isolate at each time point is presented inFIG. 1. The C13-2P and AC9 isolates produced rAAV levels similar topreviously examined adherent cell lines with 3800 and 1200 ip/cell by 48hpi, respectively, described in U.S. application Ser. No. 11/503,775,entitled Recombinant AAV Production in Mammalian Cells, filed Aug. 14,2007, which is a continuation-in-part of U.S. application Ser. No.10/252,182, entitled High Titer Recombinant AAV Production, filed Sep.23, 2002, now U.S. Pat. No. 7,091,029, issued Aug. 15, 2006, both ofwhich are incorporated by reference in their entireties herein.

Growth of Suspension BHK Cells

Clone C13-2P (referred to from this point on as “sBHK”) was selected foradditional experiments due to the higher level of rAAV production. Thegrowth of these cells was further characterized. The cells aremaintained between 2×10⁵ and 1.3×10⁶ cells/mL in DMEM supplemented with10% FBS. Numerous vials of sBHK cells have been thawed. Specifically, 33vials representing 6 banks of cells have been thawed and propagated witha mean doubling time of 11.9+/−1.9 hours (a variance of 16.3%). Incomparison, adherent 293 cells have a doubling time of ˜22-24 hours.Therefore, the faster doubling of the sBHK cells provides the advantageof faster amplification for scale-up.

Example 3 rAAV Production Over Time

The optimal harvest time of rAAV production in adherent 293 cells is48-72 hpi. Due to the faster growth rate of the sBHK cells, we wanted tore-examine the optimal time range for rAAV production in the suspensionplatform. The experiment shown in FIG. 2 demonstrated that rAAVproduction levels are similar when harvested between 24 and 69 hourspost-infection (hpi). The ability to achieve similar rAAV yields at 24hpi as at later times offers the advantages of shorter manufacturingtimes and flexibility in manufacturing schedules.

Example 4 Cell Density at Infection

Early experiments with sBHK examining rAAV production levels wereperformed with the cells infected at densities between 4.5×10⁵ and 1×10⁶cells/mL—densities that fall within the range used for routinemaintenance of the cells. However, we found that higher densities couldeasily be reached. This example addressed whether specific yields ofrAAV could be maintained upon rHSV co-infection when the cells are at ahigher density. Cell densities between 1.6×10⁶ and 3.8×10⁶ cells/mL, ata scale of 25 mL, were examined for rAAV production. The results in FIG.3 demonstrated that increasing the sBHK cell density at the time ofinfection does not impair the specific yields (per cell yields) of rAAV.The volumetric productivity (DRP/L) is directly proportional to the sBHKcell density at constant specific yield, therefore total DRP/batch canbe increased by increasing the cell density while minimizing the finalvolume required to achieve clinically relevant quantities of therapeuticvector.

Example 5 Multiplicity of Infection

The rHSV co-infection method produces optimal levels of recombinant rAAVon adherent cells when rHSV-rep2capX and rHSV-GOI are used at MOIs of 12and 2, respectively. The productions levels drop precipitously as theMOI of rHSV-rep2capX drops. Using an MOI of 12 for the rHSV-rep2capXtranslates into very large quantities of recombinant virus required whenconsidering large scale manufacturing of rAAV. This example addressedwhether the MOI of rHSV-rep2capX in co-infections on sBHK cells, unlike293 cells, could be lowered without significant loss of specific yield.The results in FIG. 4 are the cumulative data of several experimentsexamining rAAV production levels when rHSV-rep2cap2 is used at an MOI of4 to 12 (with rHSV-GOI MOI held constant at 2).

The results in FIG. 5 are the cumulative data of several experimentsexamining rAAV production levels when rHSV-rep2cap1 is used at an MOI of1 to 12. rAAV1-AAT production in sBHK cells was also insensitive torHSV-rep2/cap1 vector MOI inputs of 12, 8, and 4; however, rAAV1-AATyields dropped according with further reductions in rHSV-AAT MOI to 2and 1.

Taken together, these results demonstrate that comparable rAAVproduction can be achieved across a broad range of MOIs forrHSV-rep2capX.

Example 6 Applicability of System to Different rAAV Serotypes andDifferent Transgenes

In certain embodiments of the invention a second recombinant herpesviruscomprises a gene of interest, and a promoter operably linked to saidgene of interest. The gene of interest can be a therapeutic gene that isuseful for gene therapy applications. This example demonstrates that thesBHK system for producing rAAV vectors can be used for a variety of AAVserotypes as well as different transgenes and production scales. FIG. 6Ashows the yields of different serotypes and transgenes used in the sBHKsystem. FIG. 6B shows the DRP to infectivity ratios of representativesamples from FIG. 6A. The differences between the serotypes reflecttheir in vitro infectivity variation on the cell-type used for theinfectivity assay.

Example 7 Production of rAAV in Suspension BHK Cells in Bioreactors

Initially, sBHK rAAV2-GFP production was scaled to Celligen Pluscontinuous stirred tank reactors (CSTR) in DMEM supplemented with 5%FBS. The pH set point was 7.2, the dissolved oxygen (D.O.) set point was50% of air saturation, and the agitation set point, using marineimpellers, was 100 rpm, in a 3.5 L working volume, 5.0 L total volumejacketed glass vessel equipped with spin filters for cell retention.Reactors were seeded between 1.3-2.5×10⁵ cells/mL and grown to1.2-1.4×10⁶ cells/mL and co-infected with rHSV-rep2cap2 (MOI of 12) andrHSV-GFP (MOI of 2) to produce rAAV2-GFP. FIG. 7 shows the results.Media was exchanged at 2 hpi for DMEM lacking FBS, via tangential flowfiltration using a hollow fiber filter device for cell retention. Therun was repeated (as described above), and FIG. 8 shows similar results.

rAAV production was also scaled to 1 L/2 L (working volume/total volume)Wave disposable bioreactors. The pH set point was 7.2, the agitationrate was 20 rocks/min, the rocking angle was 7°, and total gas flowvaried between 0.1 and 0.3 L/min. Bioreactors were seeded with aninitial volume of 1.0 L at a density of 1.0-2.5×10⁵ cells/mL. Cells weregrown in fed-batch (run 1, 2, 3) or perfusion (run 4, 5) to preventnutrient depletion, and pre-infection cell growth as a function of timein 1 L/2 L Wave disposable bioreactors is shown in FIG. 9. The averagedoubling time was 13.5 h. Fed-batch runs had a bolus of 5×DMEM added at25-52 hps, and perfusion run feeding with DMEM initiated 29-42 hps, toprevent nutrient depletion as needed. Runs 1, 2, and 3 were co-infectedwith rHSV-rep2cap1 (MOI of 12) and rHSV-AAT (MOI of 2) to producerAAV1-AAT, and resulted in a specific productivity of 75,600 DRP/cell.The results are shown in FIG. 10 (1 L scale data point, n=3). Run 5 wasco-infected with the same vectors, but at a MOI of 4 and 2,respectively, based on flask data which showed rAAV1-AAT production tobe insensitive to rHSV-rep2cap1 MOI between 4 and 12 and resulted in19,252 DRP/cell by 24 hpi. Maximum cell densities for fed-batch runswere between 1.6×10⁶ and 2.3×10⁶ cells/mL while perfusion runs achieveda maximum density 1.2×10⁷ cells/mL at non-constant volume, prior toinfection, as shown in FIG. 9. Media exchange prior to infection wasaccomplished by centrifugation for fed-batch runs. FIG. 11 shows typicalmetabolite concentrations for 1 L Wave fed-batch runs. FIG. 12 showsmetabolite concentrations for a typical 1 L perfusion run.

sBHK rAAV batch production was also scaled to 5 and 10 L culture volumesin 10 L/20 L (working volume/total volume) Wave bioreactors using arHSV-rep2cap1 at an MOI of 4 and a rHSV-AAT at an MOI of 2. Cells weregrown as in 1 L Wave bioreactor cultures, with (10 L) or without (5 Land 10 L) media exchange. Media exchanged cultures grew to higherterminal cell densities since nutrients were replenished. Terminal celldensities with media exchange during growth achieved 3.1×10⁶ cells/mLprior to infection, while 2.3×10⁶ cells/mL was achieved without mediaexchange during growth. FIG. 13 shows a typical 5 L Wave disposablebioreactor culture without media exchange that resulted in apre-infection cell density of 2.3×10⁶ cells/mL. FIG. 10 shows rAAV1-AATproduction for 5 L (data point 2, n=4) and 10 L (data point 3, n=6)culture volume Wave bioreactor runs, and demonstrates that specificproductivity (DRP/cell) was maintained during scale up from 1 L to 10 Lof rAAV production in suspension-adapted cells. FIG. 14 is a graph thatshows typical sBHK cell growth at the 10 L culture volume scale in Wavebioreactor runs resulting in average doubling times of 13.1 h. FIG. 14demonstrates that spinner flask and 1 L Wave bioreactor cell growthrates were successfully scaled to 10 L Wave bioreactor productionvolumes while maintaining similar growth rates without inhibition fromammonium accumulation (Christie, A., and Butler, M.; 1999, Theadaptation of BHK cells to a non-ammoniagenic glutamate-based culturemedium. Biotechnol Bioeng 64, 298-309).

Taken together, the results presented herein described a scalable methodfor producing recombinant AAV viral particles in a mammalian cellcapable of growing in suspension.

Other Embodiments

From the foregoing description, it will be apparent that variations andmodifications may be made to the invention described herein to adopt itto various usages and conditions. Such embodiments are also within thescope of the following claims.

All patents and publications mentioned in this specification are hereinincorporated by reference to the same extent as if each independentpatent and publication was specifically and individually indicated to beincorporated by reference.

1. A method for producing recombinant AAV viral particles in a mammaliancell comprising: co-infecting a mammalian cell capable of growing insuspension with a first recombinant herpesvirus comprising a nucleicacid encoding an AAV rep and an AAV cap gene each operably linked to apromoter; and (ii) a second recombinant herpesvirus comprising a gene ofinterest, and a promoter operably linked to said gene of interest; andallowing the virus to infect the mammalian cell; thereby producingrecombinant AAV viral particles in a mammalian cell.
 2. The method ofclaim 1, wherein the gene of interest is a therapeutic gene.
 3. Themethod of claim 2, wherein the therapeutic gene is selected from thegroup consisting of: an inhibitor of anti-angiogenic genes, alpha-1antitrypsin, retinoschisin, acid alpha glucosidase, RPE65, beta-subunitof the cone photoreceptor cGMP-gated channel (CNGB-3), alpha-subunit ofthe cone photoreceptor cGMP-gated channel (CNGA-3), cone photoreceptorG-protein alpha-subunit (GNAT2), Retinal pigment epithelium-specific 65kDa (RPE65), X-linked juvenile retinoschisis (RS1), Brain-derivedneurotrophic factor (BDNF), Glial cell-derived neurotrophic factor(GDNF), Myotonic dystrophy protein kinase (DMPK), CCHC-type zinc finger,nucleic acid binding protein (known as CNBP or ZNF9), Retinitispigmentosa GTPase regulator (RPGR), Acid α-glucosidase (GAA),Choroideremia (CHM), Rab escort protein-1 (REP1), Alpha-synuclein(SNCA), Coagulation factor VIII, procoagulant component (hemophilia A orF8), Coagulation factor IX (plasma thromboplastic component, Christmasdisease, hemophilia B or F9), Aryl hydrocarbon receptor interactingprotein-like 1 (AIPL1), X-linked Inhibitor of Apoptosis Protein (XIAP),clarin-1 (CLRN1), Leber's hereditary neuropathy genes (MT-ND1, MT-ND4,MT-ND4L, and MT-ND6), alpha-galactosidase A (α-Gal A) orAlpha-L-iduronidase.
 4. The method of claim 1, wherein the AAV cap genehas a serotype selected from the group consisting of AAV-1, AAV-2,AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, and AAV-8, AAV-9, and rh-AAV-10.
 5. Amethod for producing recombinant AAV viral particles in a mammalian cellcomprising: co-infecting a mammalian cell capable of growing insuspension with a first recombinant herpesvirus comprising a nucleicacid encoding an AAV rep2 and an AAV cap1 or cap 2 gene each operablylinked to a promoter; and (ii) a second recombinant herpesviruscomprising an AI gene or an alpha 1 antitrypsin gene, and a promoteroperably linked to said gene; and allowing the virus to infect themammalian cell; thereby producing recombinant AAV viral particles in amammalian cell.
 6. The method of any of claims 1-5, wherein themammalian cell is selected from the group consisting of: BHK, HEK-293(293), Vero, RD, HT-1080, A549, Cos-7, ARPE-19, and MRC-5.
 7. A methodfor producing recombinant AAV viral particles in a BHK cell comprising:co-infecting a BHK cell capable of growing in suspension with a firstrecombinant herpesvirus comprising a nucleic acid encoding an AAV repand an AAV cap gene each operably linked to a promoter; and (ii) asecond recombinant herpesvirus comprising a gene of interest, and apromoter operably linked to said gene of interest; and allowing thevirus to infect the BHK cell; thereby producing recombinant AAV viralparticles in a BHK cell.
 8. A method for producing recombinant viralparticles in a BHK cell comprising: co-infecting a BHK cell capable ofgrowing in suspension with a first recombinant herpesvirus comprising anucleic acid encoding an AAV rep2 and an AAV cap1 or cap 2 gene eachoperably linked to a promoter; and (ii) a second recombinant herpesviruscomprising an AI gene or an alpha 1 antitrypsin gene, and a promoteroperably linked to said gene of interest; and allowing the virus toinfect the BHK cell; thereby producing recombinant viral particles in aBHK cell.
 9. The method of any one of claim 1, 5, 7 or 8, wherein theherpesvirus is a virus selected from the group consisting of:cytomegalovirus (CMV), herpes simplex (HSV) and varicella zoster (VZV)and epstein barr virus (EBV).
 10. The method of claim 9, wherein theherpesvirus is replication defective.
 11. The method of claim 7, whereinthe gene of interest is a therapeutic gene.
 12. The method of claim 11,wherein the therapeutic gene is selected from the group consisting of:anti-angiogenic genes, alpha-1 antitrypsin, retinoschisin, acid alphaglucosidase, RPE65, beta-subunit of the cone photoreceptor cGMP-gatedchannel (CNGB-3), alpha-subunit of the cone photoreceptor cGMP-gatedchannel (CNGA-3), cone photoreceptor G-protein alpha-subunit (GNAT2),Retinal pigment epithelium-specific 65 kDa (RPE65), X-linked juvenileretinoschisis (RS1), Brain-derived neurotrophic factor (BDNF), Glialcell-derived neurotrophic factor (GDNF), Myotonic dystrophy proteinkinase (DMPK), CCHC-type zinc finger, nucleic acid binding protein(known as CNBP or ZNF9), Retinitis pigmentosa GTPase regulator (RPGR),Acid α-glucosidase (GAA), Choroideremia (CHM), Rab escort protein-1(REP1), Alpha-synuclein (SNCA), Coagulation factor VIII, procoagulantcomponent (hemophilia A or F8), Coagulation factor IX (plasmathromboplastic component, Christmas disease, hemophilia B or F9), Arylhydrocarbon receptor interacting protein-like 1 (AIPL1), X-linkedInhibitor of Apoptosis Protein (XIAP), clarin-1 (CLRN1), Leber'shereditary neuropathy genes (MT-ND1, MT-ND4, MT-ND4L, and MT-ND6),alpha-galactosidase A (α-Gal A) or Alpha-L-iduronidase.
 13. The methodof claim 7, wherein the AAV cap gene has a serotype selected from thegroup consisting of AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7,AAV-8, AAV-9, and rhAAV-10.
 14. The method of any one of claims 1-13,further comprising the step of determining multiplicity of infection(MOI).
 15. The method of claim 14, wherein the MOI is between: 3 and 14.16. The method of any one of claims 1-15 wherein the co-infection issimultaneous.
 17. A method for producing recombinant viral particles ina BHK cell comprising: simultaneously co-infecting a BHK cell capable ofgrowing in suspension with a first recombinant herpesvirus comprising anucleic acid encoding an AAV rep and an AAV cap gene each operablylinked to a promoter; and (ii) a second recombinant herpesviruscomprising a gene of interest, and a promoter operably linked to saidgene of interest; allowing the virus to infect the BHK cell; andpurifying the viral particles; thereby producing recombinant viralparticles in a BHK cell.
 18. A method for producing recombinant viralparticles in a BHK cell comprising: simultaneously co-infecting a BHKcell capable of growing in suspension with a first recombinantherpesvirus comprising a nucleic acid encoding an AAV rep and an AAV capgene each operably linked to a promoter; and (ii) a second recombinantherpesvirus comprising an AI gene or an alpha 1 antitrypsin gene, and apromoter operably linked to said gene of interest; allowing the virus toinfect the BHK cell; and purifying the viral particles; therebyproducing recombinant viral particles in a BHK cell.
 19. The method ofclaim 17 or 18, wherein the herpesvirus is a virus selected from thegroup consisting of: HSV-1, HSV-2, HHV-3, HHV-4, HHV-5, HHV-6, HHV-7,and HHV-8.
 20. The method of claim 19 wherein the recombinantherpesvirus is replication defective.
 21. The method of claim 17,wherein the gene of interest is a therapeutic gene.
 22. The method ofclaim 21, wherein the therapeutic gene is selected from the groupconsisting of: AI, alpha-1 antitrypsin, retinoschisin, acid alphaglucosidase, and RPE65.
 23. The method of claim 17 or 18, wherein theAAV cap gene has a serotype selected from the group consisting of AAV-1,AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, and rhAAV-10.24. A method for producing recombinant viral particles in a mammaliancell according to any one of claims 1-23, whereby the number of viralparticles produced is equal to or greater than the number of viralparticles grown in an equal number of cells under adherent conditions.25. A recombinant AAV viral particle produced in a mammalian cell by themethod comprising co-infecting a mammalian cell capable of growing insuspension with a first recombinant herpesvirus comprising a nucleicacid encoding an AAV rep and an AAV cap gene each operably linked to apromoter; and (ii) a second recombinant herpesvirus comprising a gene ofinterest, and a promoter operably linked to said gene of interest; andallowing the virus to infect the mammalian cell; thereby producingrecombinant AAV viral particles in a mammalian cell.
 26. The recombinantviral particle of claim 25, wherein the herpesvirus is a virus selectedfrom the group consisting of: cytomegalovirus (CMV), herpes simplex(HSV) and varicella zoster (VZV) and epstein barr virus (EBV).
 27. Therecombinant viral particle of claim 26, wherein the recombinantherpesvirus is replication defective.
 28. The recombinant viral particleof claim 26, wherein the gene of interest is a therapeutic gene.
 29. Therecombinant viral particle of claim 26, wherein the therapeutic gene isselected from the group consisting of: anti-angiogenic genes, alpha-1antitrypsin, retinoschisin, acid alpha glucosidase, RPE65, beta-subunitof the cone photoreceptor cGMP-gated channel (CNGB-3), alpha-subunit ofthe cone photoreceptor cGMP-gated channel (CNGA-3), cone photoreceptorG-protein alpha-subunit (GNAT2), Retinal pigment epithelium-specific 65kDa (RPE65), X-linked juvenile retinoschisis (RS1), Brain-derivedneurotrophic factor (BDNF), Glial cell-derived neurotrophic factor(GDNF), Myotonic dystrophy protein kinase (DMPK), CCHC-type zinc finger,nucleic acid binding protein (known as CNBP or ZNF9), Retinitispigmentosa GTPase regulator (RPGR), Acid α-glucosidase (GAA),Choroideremia (CHM), Rab escort protein-1 (REP1), Alpha-synuclein(SNCA), Coagulation factor VIII, procoagulant component (hemophilia A orF8), Coagulation factor IX (plasma thromboplastic component, Christmasdisease, hemophilia B or F9), Aryl hydrocarbon receptor interactingprotein-like 1 (AIPL1), X-linked Inhibitor of Apoptosis Protein (XIAP),clarin-1 (CLRN1), Leber's hereditary neuropathy genes (MT-ND1, MT-ND4,MT-ND4L, and MT-ND6), alpha-galactosidase A (α-Gal A) orAlpha-L-iduronidase.
 30. The recombinant viral particle of claim 26,wherein the gene of interest is a reporter gene.
 31. The recombinantviral particle of claim 26, wherein the AAV cap gene has a serotypeselected from the group consisting of AAV-1, AAV-2, AAV-3, AAV-4, AAV-5,AAV-6, AAV-7, AAV-8, AAV-9, and rhAAV-10.
 32. A recombinant AAV viralparticle produced in a BHK cell comprising: co-infecting a BHK cellcapable of growing in suspension with a first recombinant herpesviruscomprising a nucleic acid encoding an AAV rep and an AAV cap gene eachoperably linked to a promoter; and (ii) a second herpesvirus comprisinga gene of interest, and a promoter operably linked to said gene ofinterest; and allowing the virus to infect the BHK cell; therebyproducing recombinant AAV viral particles in a BHK cell.
 33. A methodfor delivering a nucleic acid sequence encoding a therapeutic protein toa target cell, the method comprising: co-infecting a mammalian cellcapable of growing in suspension with a first recombinant herpesviruscomprising a nucleic acid encoding an AAV rep and an AAV cap gene eachoperably linked to a promoter; and (ii) a second herpesvirus comprisinga gene of interest, wherein the gene of interest comprises a therapeuticgene, and a promoter operably linked to said gene of interest; andallowing the virus to infect the mammalian cell and express the nucleicacid sequence encoding a therapeutic protein; thereby delivering anucleic acid sequence encoding a therapeutic protein to the target cell.34. The recombinant viral particle of claim 32 or 33, wherein theherpesvirus is a virus selected from the group consisting of:cytomegalovirus (CMV), herpes simplex (HSV) and varicella zoster (VZV)and epstein ban virus (EBV).
 35. The recombinant viral particle of claim34, wherein the recombinant herpesvirus is replication defective. 36.The recombinant viral particle of claim 33, wherein the gene of interestis a therapeutic gene.
 37. The recombinant viral particle of claim 34 or36, wherein the therapeutic gene is selected from the group consistingof: anti-angiogenic genes, alpha-1 antitrypsin, retinoschisin, acidalpha glucosidase, RPE65, beta-subunit of the cone photoreceptorcGMP-gated channel (CNGB-3), alpha-subunit of the cone photoreceptorcGMP-gated channel (CNGA-3), cone photoreceptor G-protein alpha-subunit(GNAT2), Retinal pigment epithelium-specific 65 kDa (RPE65), X-linkedjuvenile retinoschisis (RS1), Brain-derived neurotrophic factor (BDNF),Glial cell-derived neurotrophic factor (GDNF), Myotonic dystrophyprotein kinase (DMPK), CCHC-type zinc finger, nucleic acid bindingprotein (known as CNBP or ZNF9), Retinitis pigmentosa GTPase regulator(RPGR), Acid α-glucosidase (GAA), Choroideremia (CHM), Rab escortprotein-1 (REP1), Alpha-synuclein (SNCA), Coagulation factor VIII,procoagulant component (hemophilia A or F8), Coagulation factor IX(plasma thromboplastic component, Christmas disease, hemophilia B orF9), Aryl hydrocarbon receptor interacting protein-like 1 (AIPL1),X-linked Inhibitor of Apoptosis Protein (XIAP), clarin-1 (CLRN1),Leber's hereditary neuropathy genes (MT-ND1, MT-ND4, MT-ND4L, andMT-ND6), alpha-galactosidase A (α-Gal A) or Alpha-L-iduronidase.
 38. Therecombinant viral particle of claim 33 or 34, wherein the AAV cap genehas a serotype selected from the group consisting of AAV-1, AAV-2,AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, and rhAAV-10.
 39. A kitfor making a recombinant viral particle in a mammalian cell that iscapable of growing in suspension, and instructions for use.
 40. A kitfor delivering a nucleic acid sequence encoding a therapeutic protein toa target cell according to claim 33, and instructions for use.